Kristina Bubulytė¹, Pijus Ruokis¹

¹Lithuanian University of Health Sciences, Medicine academy, faculty of Medicine

Abstract. Covid-19 disease is a respiratory disease caused by the SARS-CoV-2 virus. In severe cases the disease presents itself with coagulation disorders, the most common complications of which are pulmonary artery thromboembolism (PATE), venous and arterial thrombosis, and disseminated intravascular coagulation (DIC). Studies have shown that PATE emerged in about 20.6% and arterial thrombosis in 3.7%. of patients treated in Covid-19 intensive care units. DIC, meanwhile, is found in 0.6 % recovered and in 71.4 % deceased from the Covid-19 infection. Covid-19-induced hypercoagulation is explained by an increased inflammatory response and the direct cytotoxicity of the SARS-CoV-2 virus to vascular endothelial cells, causing endothelial damage and thus activating clotting cascades. Prophylactic doses of low molecular weight heparins (LMWH) are currently used to prevent Covid-19-induced coagulation disorders, but such treatment is insufficient in severe disease progression.

Objective: in this article, we will review the main thromboembolic complications of Covid-19 emergent coagulopathy, Covid-19 emergent coagulopathy pathogenesis and its’ treatment possibilities.

Methods: literature and data search was done using PubMed, ScienceDirect and other medical databases from March 2021 until May 2021. Scientific literature sources not older than five years were selected for the analysis.

Keywords: Covid-19, coagulation, coagulopathy.